TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
SPRY

ARS Pharmaceuticals, Inc

Healthcare · Biotechnology · —

4.10$ -1.0% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement SPRY
Line item 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
78.9% 3.9% 1,300.9% 243.3% 23.1% 24.2%
21.1% 96.1% -1,200.9% 100.0% 76.9% 75.8%
78.9% 368.2% 1,396.4% 67,553.3% 22.0% 15.6%
23.7% 85.1% 1,402.4% 157,613.3% 80.4% 273.1%
23.7% 449.5% 1,497.9% 225,166.7% 80.4% 288.7%
-2.6% -353.3% -2,698.8% -225,066.7% -3.5% -212.9%
0.2% 1.9% 63.4% 0.0% 3.1%
-6.0% -367.7% -2,635.4% -181,216.7% 9.3% -203.3%
-1.1% -4.2% -52.7% -316.3% 0.3% -0.1%
-6.0% -367.7% -2,635.4% -181,216.7% 9.0% -203.3%
-2.6% -361.9% -2,611.2% -180,973.3% 9.4% -198.6%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?